Pathos AI Raises $237M at $3B Valuation — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pathos AI said Friday it raised a $237 million Series E at a $3 billion post-money valuation; the company uses AI to develop oncology drugs and describes itself as a precision oncology biotech.
- Pathos AI's new $3 billion post-money valuation is up from $1.6 billion after its $365 million Series D in May 2025.
Why it matters: Pathos AI's price tag nearly doubled, from $1.6 billion to $3 billion, even as the new check — $237 million — is smaller than the $365 million Series D it closed in May 2025. Backers are buying into the same AI-oncology platform at a far higher price with less new capital committed.
Ask SkimNews
